Christine C. Roberts

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

Darron R. Brown, Susanne K. Kjær, Kristján Sigurðsson et al. · The Journal of Infectious Diseases · 2009 · 627 citations · Full text

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

Nubia Muñóz, Susanne K. Kjær, Kristján Sigurðsson et al. · JNCI Journal of the National Cancer Institute · 2010 · 562 citations · Full text

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Warner K. Huh, Elmar A. Joura, Anna R. Giuliano et al. · The Lancet · 2017 · 448 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +11

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

Susanne K. Kjær, Kristján Sigurðsson, Ole‐Erik Iversen et al. · Cancer Prevention Research · 2009 · 324 citations · Full text

Gynecology, Cervical Cancer Prevention, Continued Prophylactic Efficacy +20

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Kayvon Modjarrad, Christine C. Roberts, Kristin T Mills et al. · The Lancet Infectious Diseases · 2019 · 314 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7